Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 16Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

Etoposide 10Cisplatin 7Carboplatin 6tislelizumab 2camrelizumab 2atezolizumab 2anlotinib 2Topotecan 2Irinotecan 2Drug Therapy 2Bevacizumab 2temsirolimus 1spartalizumab 1oblimersen 1obinutuzumab 1lutetium Lu 177 dotatate 1gossypol acetic acid 1durvalumab 1ceralasertib 1apatinib 1Temozolomide 1Sirolimus 1Podophyllotoxin 1Platinum 1Paclitaxel 1NVP-BKM120 1Injections 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × anlotinib × Clear all
NCT05896059 2023-06-09

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Zhejiang Cancer Hospital

Phase 2 Unknown
21 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04933175 2021-06-21

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Fujian Provincial Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡